Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 2
2014 5
2015 5
2016 5
2017 11
2018 6
2020 1
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Results by year

Filters applied: . Clear all
Page 1
Cell-based therapeutic strategies for multiple sclerosis.
Scolding NJ, Pasquini M, Reingold SC, Cohen JA; International Conference on Cell-Based Therapies for Multiple Sclerosis; International Conference on Cell-Based Therapies for Multiple Sclerosis; International Conference on Cell-Based Therapies for Multiple Sclerosis. Scolding NJ, et al. Brain. 2017 Nov 1;140(11):2776-2796. doi: 10.1093/brain/awx154. Brain. 2017. PMID: 29053779 Free PMC article. Review.
Cell Therapy for Multiple Sclerosis.
Sarkar P, Rice CM, Scolding NJ. Sarkar P, et al. CNS Drugs. 2017 Jun;31(6):453-469. doi: 10.1007/s40263-017-0429-9. CNS Drugs. 2017. PMID: 28397112 Review.
Cell fusion in the brain: two cells forward, one cell back.
Kemp K, Wilkins A, Scolding N. Kemp K, et al. Acta Neuropathol. 2014 Nov;128(5):629-38. doi: 10.1007/s00401-014-1303-1. Epub 2014 Jun 5. Acta Neuropathol. 2014. PMID: 24899142 Free PMC article. Review.
Can the optic nerve be repaired?
Wilkins A, Scolding N. Wilkins A, et al. Lancet Neurol. 2017 Mar;16(3):172-173. doi: 10.1016/S1474-4422(16)30402-1. Epub 2017 Feb 15. Lancet Neurol. 2017. PMID: 28229881 No abstract available.
Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.
Kalincik T, Brown JWL, Robertson N, Willis M, Scolding N, Rice CM, Wilkins A, Pearson O, Ziemssen T, Hutchinson M, McGuigan C, Jokubaitis V, Spelman T, Horakova D, Havrdova E, Trojano M, Izquierdo G, Lugaresi A, Prat A, Girard M, Duquette P, Grammond P, Alroughani R, Pucci E, Sola P, Hupperts R, Lechner-Scott J, Terzi M, Van Pesch V, Rozsa C, Grand'Maison F, Boz C, Granella F, Slee M, Spitaleri D, Olascoaga J, Bergamaschi R, Verheul F, Vucic S, McCombe P, Hodgkinson S, Sanchez-Menoyo JL, Ampapa R, Simo M, Csepany T, Ramo C, Cristiano E, Barnett M, Butzkueven H, Coles A; MSBase Study Group. Kalincik T, et al. Lancet Neurol. 2017 Apr;16(4):271-281. doi: 10.1016/S1474-4422(17)30007-8. Epub 2017 Feb 11. Lancet Neurol. 2017. PMID: 28209331 Free article.
29 results